Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

Research output: Contribution to journalArticlepeer-review

1599 Citations (Scopus)

Abstract

As trials of 5 years of tamoxifen in early breast cancer mature, the relevance of hormone receptor measurements (and other patient characteristics) to long-term outcome can be assessed increasingly reliably. We report updated meta-analyses of the trials of 5 years of adjuvant tamoxifen.
Original languageEnglish
Pages (from-to)771-84
Number of pages14
JournalThe Lancet
Volume378
Issue number9793
DOIs
Publication statusPublished - 27 Aug 2011

Keywords

  • Randomized Controlled Trials as Topic
  • Receptors, Progesterone
  • Neoplasms, Second Primary
  • Antineoplastic Agents, Hormonal
  • Humans
  • Breast Neoplasms
  • Neoplasm Recurrence, Local
  • Selective Estrogen Receptor Modulators
  • Tamoxifen
  • Female
  • Chemotherapy, Adjuvant
  • Receptors, Estrogen

Fingerprint

Dive into the research topics of 'Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials'. Together they form a unique fingerprint.

Cite this